BioPorto (BIOPOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-15.68 Million ≈ $-2.45 Million USD) by net assets (Dkr63.01 Million ≈ $9.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BioPorto (BIOPOR) total market value for the company's overall valuation and market capitalisation.
BioPorto - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioPorto Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency. Explore BIOPOR cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EcoSynthetix Inc
TO:ECO
|
0.014x |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
-0.623x |
|
Blink Charging Co
NASDAQ:BLNK
|
0.011x |
|
Transart Graphics Co Ltd
TW:8481
|
0.021x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.165x |
|
Al-Salam Real Estate Investment Trust
KLSE:5269
|
0.068x |
|
Rallybio Corp
NASDAQ:RLYB
|
0.482x |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
0.116x |
Annual Cash Flow Conversion Efficiency for BioPorto (2000–2025)
The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2025. View latest BioPorto stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr63.01 Million ≈ $9.86 Million |
Dkr-77.07 Million ≈ $-12.06 Million |
-1.223x | +0.82% |
| 2024-12-31 | Dkr67.78 Million ≈ $10.60 Million |
Dkr-83.58 Million ≈ $-13.08 Million |
-1.233x | -33.78% |
| 2023-12-31 | Dkr60.16 Million ≈ $9.41 Million |
Dkr-55.46 Million ≈ $-8.68 Million |
-0.922x | -23.33% |
| 2022-12-31 | Dkr70.22 Million ≈ $10.99 Million |
Dkr-52.48 Million ≈ $-8.21 Million |
-0.747x | +46.80% |
| 2021-12-31 | Dkr45.96 Million ≈ $7.19 Million |
Dkr-64.58 Million ≈ $-10.10 Million |
-1.405x | -298.07% |
| 2020-12-31 | Dkr100.91 Million ≈ $15.79 Million |
Dkr-35.62 Million ≈ $-5.57 Million |
-0.353x | +85.15% |
| 2019-12-31 | Dkr25.32 Million ≈ $3.96 Million |
Dkr-60.16 Million ≈ $-9.41 Million |
-2.376x | -251.29% |
| 2018-12-31 | Dkr56.20 Million ≈ $8.79 Million |
Dkr-38.01 Million ≈ $-5.95 Million |
-0.676x | -28.99% |
| 2017-12-31 | Dkr56.07 Million ≈ $8.77 Million |
Dkr-29.40 Million ≈ $-4.60 Million |
-0.524x | -18.13% |
| 2016-12-31 | Dkr44.29 Million ≈ $6.93 Million |
Dkr-19.66 Million ≈ $-3.08 Million |
-0.444x | -19.14% |
| 2015-12-31 | Dkr44.48 Million ≈ $6.96 Million |
Dkr-16.57 Million ≈ $-2.59 Million |
-0.373x | +33.77% |
| 2014-12-31 | Dkr28.69 Million ≈ $4.49 Million |
Dkr-16.14 Million ≈ $-2.52 Million |
-0.563x | -44.91% |
| 2013-12-31 | Dkr42.86 Million ≈ $6.71 Million |
Dkr-16.64 Million ≈ $-2.60 Million |
-0.388x | -102.92% |
| 2012-12-31 | Dkr-1.15 Million ≈ $-179.93K |
Dkr-15.28 Million ≈ $-2.39 Million |
13.287x | +484.76% |
| 2011-12-31 | Dkr3.94 Million ≈ $616.44K |
Dkr-13.61 Million ≈ $-2.13 Million |
-3.453x | +14.59% |
| 2010-12-31 | Dkr3.31 Million ≈ $517.72K |
Dkr-13.38 Million ≈ $-2.09 Million |
-4.043x | -368.99% |
| 2009-12-31 | Dkr15.41 Million ≈ $2.41 Million |
Dkr-13.29 Million ≈ $-2.08 Million |
-0.862x | +2.57% |
| 2008-12-31 | Dkr15.50 Million ≈ $2.43 Million |
Dkr-13.72 Million ≈ $-2.15 Million |
-0.885x | -84.47% |
| 2007-12-31 | Dkr29.45 Million ≈ $4.61 Million |
Dkr-14.13 Million ≈ $-2.21 Million |
-0.480x | -62897.70% |
| 2006-12-31 | Dkr-17.62 Million ≈ $-2.76 Million |
Dkr-13.46K ≈ $-2.11K |
0.001x | -83.18% |
| 2005-12-31 | Dkr-3.06 Million ≈ $-478.13K |
Dkr-13.88K ≈ $-2.17K |
0.005x | -99.19% |
| 2000-12-31 | Dkr894.00K ≈ $139.87K |
Dkr503.00K ≈ $78.70K |
0.563x | -- |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more